Journal Article

In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China

Wu, Shi, Hu, Fupin, Guo, Yan, Zhu, Demei, Yin, Dandan, Yang, Yang, Zhi, Peiyuan

2022

Overview

To evaluate in vitro antibacterial activity of MRX-8 against gram-negative bacteria recently isolated from China, 765 clinical isolates were collected randomly from 2017 to 2020, including Enterobacterales and P. aeruginosa and A. baumannii , S. maltophilia, B. cepacia, Alcaligenes app. and Haemophilus spp. isolates. All strains were performed with antimicrobial susceptibility testing by broth microdilution method according to the CLSI 2021. Antimicrobial agents included MRX-8, polymyxin B, colistin, amikacin, ceftriaxone, ceftazidime, cefepime, ceftazidime-avibactam, cefoperazone-sulbactam, meropenem, ciprofloxacin, ampicillin, ampicillin-sulbactam and levofloxacin. For carbapenem-susceptible and carbapenem-resistant E.coli isolates, the MIC 50/90 of MRX-8 was 0.125/0.25 mg/L and 0.06/0.125 mg/L, respectively. For carbapenem-susceptible and carbapenem-resistant K. pneumoniae isolates, the MIC 50/90 of MRX-8 was 0.25/0.5 mg/L and 0.125/0.5 mg/L, respectively. For polymyxins (polymyxin B and colistin)-resistant E. coli and K. pneumoniae , MIC 50 of MRX-8 was 4-16 mg/L and MIC 90 was >32 mg/L. The MIC 50 and MIC 90 of MRX-8 for other Klebsiella spp. except K. pneumoniae , Citrobacter spp., S. enterica and Shigella spp. isolates ranged 0.06-0.125 mg/L and 0.06-0.25mg/L, respectively. For Morganella spp. , Proteus spp. , Providencia spp. , Serratia spp., S. maltophilia and B. cepacia , all MIC 50 of MRX-8 was >32mg/L. For carbapenem susceptible and resistant P. aeruginosa , the MIC 50 and MIC 90 of MRX-8 was both 1mg/L, and that for A. baumannii was 0.5mg/L and 0.5-1mg/L. For Alcaligenes spp. and Haemophilus spp., MIC 50/90 was 1/4 mg/L and 0.25/0.5 mg/L. MRX-8 was more effective against most clinically isolated gram-negative isolates, including carbapenem-resistant E. coli , K. pneumoniae , P. aeruginosa and A. baumannii , highlighting its potential as valuable therapeutics.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Alcaligenes / Amikacin / Ampicillin / Antibacterial activity / Antimicrobial agents / Bacteria / Bacterial infections / Carbapenems / Cefepime / Cefoperazone / Ceftazidime / Ceftriaxone / Cellular and Infection Microbiology / Ciprofloxacin / Clinical isolates / Clinical medicine / Colistin / Drug resistance / E coli / Escherichia coli / Gram-negative bacilli / Gram-Negative Bacteria / Haemophilus / Klebsiella pneumoniae / Levofloxacin / Meropenem / Microbial Sensitivity Tests / minimal inhibitory concentration / MRX-8 / Pathogens / Polymyxin B / Polymyxins / Pseudomonas aeruginosa / Quality control / Salmonella / Sulbactam